Warning message

This article was published in April 2016. The information may be out of date. Please check our epilepsy information or our site A-Z.

Survey launched to measure awareness about sodium valproate among women of childbearing age

25 Apr 2016

Three of the UK’s epilepsy charities have created a survey to assess how aware women aged 16-50 are about the possible risks of taking sodium valproate during pregnancy. It launched on Monday, April 18 and will run for the next six weeks.

Epilepsy Action, Epilepsy Society and Young Epilepsy put the survey together with the help of the Medicines and Healthcare products Regulatory Agency (MHRA). The survey will also aim to find out how well healthcare professionals explain possible risks of taking this medication to women with epilepsy.

Valproate-based medicines are used to treat epilepsy as well as other conditions like bipolar disorder. Valproate medicines for epilepsy are sold under brand names like Epilim, Epilim Chrono, Epilim Chronosphere, Episenta and Epival.

According to the MHRA, around four in 10 babies born to mothers taking valproate are at risk of a developmental disorder. About one in 10 babies is at risk of being born with physical birth defects.

The MHRA released a toolkit in February this year to help healthcare professionals inform women with epilepsy about these risks. The survey will hope to gauge how effective this toolkit has been so far.

Epilepsy Action believes women of a childbearing age taking sodium valproate should ask their doctors about risks and discuss their options. It is important that women do not stop taking their medication before speaking to their doctors, as they may risk a breakthrough seizure.

You can take the survey here.

 

You may also like...

Toolkit launched to help clinicians inform women of the risks of valproate medicines in pregnancy

A new toolkit has been launched today to help medical professionals inform women about the risks of taking valproate medicines during pregnancy.

There are no comments yet. Be the first to comment...

Question about your epilepsy?

Your question will be sent to our helpline advisors.

Have a comment about this page?

All comments are reviewed by a moderator before publishing. Comments will be edited or deleted if they are offensive, libellous, slanderous, abusive, commercial or irrelevant.

We ask for your email when you make a comment through this website. This means that we can let you know directly that we have replied to you. By making a comment through the website, you allow us to use the comment in our publicity without using your name. If we would like to use your name, we will email you to get your permission.

The content of this field is kept private and will not be shown publicly.
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
4 + 9 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.